BofA raises GE HealthCare stock price target to $84 on growth
BofA raised its price target for GE HealthCare (GEHC) to $84 from $74, citing strong Q3 growth and better order performance. The company reported 6.2% organic growth, exceeding estimates, but guided Q4 growth below expectations. GEHC's revenue reached $5.51B in Q3, with EPS up 25.1% YoY. Stifel also raised its target to $90, maintaining a Buy rating.
How this was made
The 30-second read
Why it matters
The higher target may attract new buying, but investors should watch Q4 guidance and backlog trends for downside risk.
Market read
Analyst target raise is a fresh catalyst that could move GEHC modestly in the short term.
What to watch
Potential headwinds from the $45 million product hold and a declining backlog could temper upside.
Background
BofA Securities upgraded its valuation on GE HealthCare after the company reported Q3 organic growth of 6.2% and raised its margin guidance.
Ticker impact
BofA Securities raised its price target on GE HealthCare to $84 from $74, citing stronger Q3 growth and higher peer multiples.
likely upward pressure as investors price in the higher valuation multiple.
The target raise is a fresh analyst action with a $10 increase, indicating improved expectations.
Market effects
The upgrade may lift sentiment across the health‑care equipment sector as peers are re‑rated.
U.S. markets could see modest buying in health‑care stocks following the target raise.
Limited to investors tracking U.S. health‑care equities; no direct global macro effect.
Counterpoint
The price target increase may be premature if Q4 guidance below consensus leads to a pullback.
Key entities
- companyGE HealthCare
U.S.-listed health‑care equipment and services provider (ticker GEHC).
- analystBofA Securities
Bank of America research unit that issued the price‑target raise.
